 This is an open-label, single-arm, ascending dose Phase III study of BIO 300 Oral Suspension given in combination with paclitaxelcarboplatin and radiotherapy in subjects with stage II, III, or IV NSCLC who are candidates for combined chemoradiotherapy. 